利用陽離子交換及膠質過濾層析,我們從Crotalus atrox蛇毒中分離出一個具有抗凝血活性的蛋白成分,並命名為Croatroxase。它的分子量經由SDS-PAGE測定為27 kDa。在50 .mu.g/ml的Croatroxase前處理30分鐘之後,純化的fibrinogen不再具有形成clot的活性。另外隨著Croatroxase存在量的增加,血漿加鈣後引發血漿凝固的時間亦隨之延長。4 .mu.g/ml的Croatroxase即可使得加鈣的血漿在10分鐘內無法凝固。Croatroxase 延長血漿加鈣凝固時間的作用與其和血漿先行作用時間的長短並無相關性。當4 .mu.g/ml的Croatroxase完全抑制血漿凝固的同時,ADP (10 .mu.M)所引發血漿中血小板的凝集則不受影響。這樣的結果顯示Croatroxase只干擾血液凝固並不會影響血小板的凝集功能。 A protein with anticoagulant activity was purified from snake venom of Crotalus atrox by cation-exchange in SP Sepharose column and gel-filtration in Sephacryl S-100 column. This protein was called croatroxase and its moleclar weight was estimated to be 27 kDa by SDS-PAGE. After 30 min pretreatment, croatroxase rendered purified fibrinogen incoagulable at 50 .mu.g/ml. Croatroxase was also active in human plasma. It prolonged plasma recalcification time in a dose-dependent manner. At 4 .mu.g/ml, croatroxase prevented clot formation longer than 10 min, however, it had no significant effect on platelet aggregation induced by ADP (10 .mu.M) in platelet-rich plasma. These results indicated that croatroxase as an anticoagulant without effet on platelet aggregation.
